Aptose Biosciences Publishes Promising Preclinical Data on Tuspetinib

Aptose Biosciences ( (TSE:APS) ) has shared an announcement.

Aptose Biosciences announced the publication of preclinical data on its lead compound tuspetinib (TUS) in the AACR journal, demonstrating its unique mechanism of action and synthetic lethality when combined with venetoclax (VEN) in acute myeloid leukemia (AML) cells. The findings highlight TUS’s potential as a broad antileukemic agent, particularly in overcoming resistance in AML models, and its favorable safety profile. Aptose is advancing clinical trials for newly diagnosed AML patients using the TUS+VEN+AZA triplet therapy, building on promising results from trials in relapsed or refractory AML patients.

More about Aptose Biosciences

Aptose Biosciences is a clinical-stage biotechnology company focused on precision oncology, with a primary focus on hematology. It develops targeted agents like the oral kinase inhibitor tuspetinib (TUS) to treat hematologic malignancies, aiming to provide efficacy both as a monotherapy and in combination with other anti-cancer therapies.

YTD Price Performance: -92.80%

Average Trading Volume: 463,691

Technical Sentiment Consensus Rating: Strong Buy

Current Market Cap: $10.94M

For an in-depth examination of APS stock, go to TipRanks’ Stock Analysis page.